SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Poudarki četrte četrtine 2023 (all comparisons are to the prior year period)
- Worldwide revenue of $38.9 million, representing an increase of ~22%
- U.S. revenue of $36.7 million, representing an increase of ~22%
- Gross Margin of ~74%, reflecting a ~4 percentage point reduction from excess inventory reserve
- Over 1,130 active physicians, representing an increase of ~22%
- Cash and equivalents of ~$166 million, representing net cash usage of ~$0.8 million
Fiscal Year 2023 Highlights (all comparisons are to the prior year period)
- Worldwide revenue of $138.9 million, representing an increase of ~31%
- U.S. revenue of $130.6 million, representing an increase of ~32%
- Gross Margin of ~79%, reflecting a ~1 percentage point reduction from excess inventory reserve
- Over 1,600 physicians performed more than 15,000 procedures in the U.S.
Najnovejši operativni poudarki
- Received 510(k) clearance for smaller diameter iFuse Bedrock Granite implant, with S1 and pediatric deformity indication
- Published early SILVIA results which demonstrate the feasibility and safety of pelvic fixation and fusion with iFuse-3D and highlighted the prevalence of SI joint pain in 16% of the patients undergoing deformity surgery
- Built on the success of iFuse TORQ with interventional spine physicians and completed the first SI joint allograft procedure, reimbursed under CPT 27278, using iFuse INTRA
“2023 was a year of records for us, as our annual worldwide revenue growth exceeded 30%, led by over 32% procedure volume growth in the U.S. I am proud of our team’s stellar execution as we supported a record 1,600 U.S. physicians to help improve the lives of nearly 15,000 patients in the U.S., while driving substantial operating leverage and reduction in cash usage,” said Laura Francis, Chief Executive Officer. “I expect 2024 to be an exciting year for us as we capitalize on favorable demand dynamics, launch products across each of our target markets, and make significant progress toward our Adjusted EBITDA breakeven goal.”
Četrti četrtletje 2023 Finančni rezultati
Worldwide revenue was $38.9 million in the fourth quarter 2023, a ~22% increase from $32.0 million in the corresponding period in 2022. U.S. revenue for the fourth quarter 2023 was $36.7 million, an increase of ~22% from $30.0 million in the corresponding period in 2022. International revenue was $2.2 million in the fourth quarter 2023 compared to $2.0 million in the corresponding period in 2022.
Gross margin was ~74% for the fourth quarter 2023, compared to ~84% in the corresponding period in 2022. Gross margin in the fourth quarter 2023 was impacted by procedure and product mix as well as the impact of higher depreciation from instrument trays, depreciation associated with our second facility in Santa Clara, and higher freight costs. The fourth quarter 2023 gross margin also reflects a ~4 percentage point reduction from a $1.7 million excess inventory reserve.
Operating expenses increased ~8% to $41.2 million in the fourth quarter 2023, compared to $38.2 million in the corresponding period in 2022. The change in operating expenses was primarily driven by higher commission related to revenue growth, increase in compensation as well as research and development investments.
Net loss improved by ~2% to $11.0 million, or $0.27 per diluted share for the fourth quarter 2023, as compared to a net loss of $11.2 million, or $0.32 per diluted share in the corresponding period in 2022. Net loss per diluted share for the fourth quarter 2023 includes the impact of the increase in shares outstanding as a result of the follow-on common stock offering in May 2023.
Adjusted EBITDA loss, including the $1.7 million impact from excess inventory reserve, declined by approximately ~16% to $4.8 million in the fourth quarter 2023 compared to an adjusted EBITDA loss of $4.2 million in the corresponding period in 2022.
2023 Finančni rezultati
Worldwide revenue was $138.9 million for 2023, a ~31% increase from $106.4 million in 2022. U.S. revenue for 2023 was $130.6 million, a ~32% increase from $98.8 million in 2022. International revenue was $8.3 million in 2023 compared to $7.7 million in 2022.
Gross margin was ~79% for 2023, compared to ~85% in 2022. In 2023, gross margin was impacted by procedure and product mix, higher depreciation from instrument trays, depreciation associated with the second facility in Santa Clara, and freight costs. The 2023 gross margin reflects a ~1 percentage point reduction from excess inventory reserve.
Operating expenses increased ~4% to $156.4 million in 2023, compared to $150.3 million in 2022. The change in operating expenses was primarily driven by higher commission related to revenue growth, increase in compensation as well as research and development investments offset by timing of certain commercial activity, lower headcount and travel costs.
Net loss improved by ~29% to $43.3 million, or $1.13 per diluted share for 2023, as compared to a net loss $61.3 million, or $1.79 per diluted share in 2022. Net loss per diluted share for 2023 includes the impact of the increase in shares outstanding as a result of the follow-on common stock offering in May 2023.
Adjusted EBITDA loss, which includes the impact of excess inventory reserve, improved by ~48% to $17.3 million for 2023, compared to an adjusted EBITDA loss of $33.2 million in 2022.
Cash and marketable securities were ~$166.0 million as of December 31, 2023.
2024 Finančne smernice
SI-BONE expects 2024 worldwide revenue of $162 million to $165 million, implying year-over-year growth of ~17% to ~19%. SI-BONE estimates fiscal year 2024 gross margin to be ~78% and operating expenses growth to be ~9%. Based on these assumptions, SI-BONE expects significant year-over-year improvement in Adjusted EBITDA loss for full year 2024.
Informacije o spletnem prenosu in konferenčnih klicih
SI-BONE will host a conference call to discuss the fourth quarter 2023 financial results after market close on Monday, February 26, 2024 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/px3jaycu. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
O SI-BONE
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 physicians in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
Za dodatne informacije o podjetju ali izdelkih, vključno s tveganji in koristmi, obiščite www.si-bone.com.
iFuse Bedrock Granite, iFuse-TORQ and SI-BONE are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.
Napovedne izjave
The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, contained in this press release are “forward-looking” statements. These forward-looking statements are based on SI-BONE’s current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE’s ability to introduce and commercialize new products and indications, SI-BONE’s ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE’s devices, SI-BONE’s ability to manage risks to its supply chain, and future capital requirements driven by new surgical systems requiring investment in instrument trays and implant inventory. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company’s most recent filings on Form 10-K and Form 10-Q, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov), especially under the caption “Risk Factors”. SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Uporaba finančnih ukrepov, ki niso GAAP
SI-BONE uses Adjusted EBITDA, a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation. SI-BONE believes the presentation of Adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management’s performance. SI-BONE also believes the presentation of Adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.
Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because Adjusted EBITDA excludes the effect of items that increase or decrease the Company’s reported results of operations, management strongly encourages investors to review, when they become available, the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company’s definition of Adjusted EBITDA may differ from similarly titled measures used by others.
Kontakt z vlagatelji
Saqib Iqbal
Director, FP&A and Investor Relations
investitor@SI-BONE.com
SI-BONE, INC. ZBIRANI KONSOLIDIRANI IZKAZI O POSLOVANJU (V tisočih, razen delnic in zneskov na delnico) (nerevidirano) |
||||||||||||||||
Trije meseci, končani 31. decembra, | Leto, ki se je končalo 31. decembra, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
prihodki | $ | 38,859 | $ | 31,953 | $ | 138,886 | $ | 106,409 | ||||||||
Cena prodanega blaga | 10,183 | 5,089 | 29,466 | 15,705 | ||||||||||||
Bruto dobiček | 28,676 | 26,864 | 109,420 | 90,704 | ||||||||||||
Bruto marža | 74 | % | 84 | % | 79 | % | 85 | % | ||||||||
Poslovni odhodki: | ||||||||||||||||
Prodaja in trženje | 28,937 | 27,609 | 110,254 | 107,726 | ||||||||||||
Raziskave in razvoj | 4,162 | 3,480 | 15,028 | 13,627 | ||||||||||||
Splošno in upravno | 8,083 | 7,069 | 31,069 | 28,960 | ||||||||||||
Skupni stroški poslovanja | 41,182 | 38,158 | 156,351 | 150,313 | ||||||||||||
Izguba iz poslovanja | (12,506 | ) | (11,294 | ) | (46,931 | ) | (59,609 | ) | ||||||||
Interest and other income (expense), net: | ||||||||||||||||
Dohodek od obresti | 2,228 | 749 | 6,916 | 1,304 | ||||||||||||
Odhodki za obresti | (890 | ) | (881 | ) | (3,462 | ) | (2,819 | ) | ||||||||
Drugi prihodki (odhodki), neto | 185 | 251 | 141 | (132 | ) | |||||||||||
Čista izguba | $ | (10,983 | ) | $ | (11,175 | ) | $ | (43,336 | ) | $ | (61,256 | ) | ||||
Čista izguba na delnico, osnovna in razredčena | $ | (0.27 | ) | $ | (0.32 | ) | $ | (1.13 | ) | $ | (1.79 | ) | ||||
Weighted-average number of common shares used to compute basic and diluted net loss per share | 40,579,409 | 34,594,536 | 38,427,419 | 34,201,824 |
SI-BONE, INC. ZDRUŽENA KONSOLIDIRANA BILANCA STANJA (v tisočih) (nerevidirano) |
||||||||
December 31, | ||||||||
2023 | 2022 | |||||||
SREDSTVA | ||||||||
Kratkoročna sredstva: | ||||||||
Denar in denarni ustrezniki | $ | 33,271 | $ | 20,717 | ||||
Kratkoročne naložbe | 132,748 | 76,573 | ||||||
Terjatve do kupcev, neto | 21,953 | 20,674 | ||||||
popis | 20,249 | 17,282 | ||||||
Vnaprej plačani odhodki in druga obratna sredstva | 3,173 | 2,365 | ||||||
Skupna kratkoročna sredstva | 211,394 | 137,611 | ||||||
Nepremičnine in oprema, neto | 16,000 | 15,564 | ||||||
Sredstva za pravico do uporabe, ki jih ima poslovni najem | 2,706 | 4,002 | ||||||
Druga dolgoročna sredstva | 325 | 375 | ||||||
SKUPNA SREDSTVA | $ | 230,425 | $ | 157,552 | ||||
OBVEZNOSTI IN KAPITAL DELOVNIH DRUŽB | ||||||||
Kratkoročne obveznosti: | ||||||||
Obveznosti za plačilo | $ | 4,588 | $ | 6,279 | ||||
Natečene obveznosti in drugo | 17,452 | 13,511 | ||||||
Obveznosti iz poslovnega najema, kratkoročni del | 1,416 | 1,388 | ||||||
Skupne kratkoročne obveznosti | 23,456 | 21,178 | ||||||
Dolgoročna posojila | 36,065 | 35,171 | ||||||
Obveznosti iz poslovnega najema, brez tekočega dela | 1,511 | 2,871 | ||||||
Druge dolgoročne obveznosti | 18 | 30 | ||||||
SKUPAJ OBVEZNOSTI | 61,050 | 59,250 | ||||||
Kapital delničarjev: | ||||||||
Navadne delnice in dodatni vplačani kapital | 569,481 | 455,175 | ||||||
Nakopičeni drug vseobsegajoči dohodek | 335 | 232 | ||||||
Akumulirani primanjkljaj | (400,441 | ) | (357,105 | ) | ||||
SKUPAJ LASTNIŠKI KAPITAL | 169,375 | 98,302 | ||||||
SKUPAJ OBVEZNOSTI IN LASTNIŠKI KAPITAL | $ | 230,425 | $ | 157,552 |
SI-BONE, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (V tisočih) (nerevidirano) |
||||||||||||||||
Trije meseci, končani 31. decembra, | Leto, ki se je končalo 31. decembra, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Čista izguba | $ | (10,983 | ) | $ | (11,175 | ) | $ | (43,336 | ) | $ | (61,256 | ) | ||||
Dohodek od obresti | (2,228 | ) | (749 | ) | (6,916 | ) | (1,304 | ) | ||||||||
Odhodki za obresti | 890 | 881 | 3,462 | 2,819 | ||||||||||||
Amortizacija | 1,573 | 1,002 | 5,428 | 3,452 | ||||||||||||
Odškodnina na podlagi zalog | 5,937 | 5,881 | 24,057 | 23,061 | ||||||||||||
Prilagojena EBITDA | $ | (4,811 | ) | $ | (4,160 | ) | $ | (17,305 | ) | $ | (33,227 | ) | ||||
- Distribucija vsebine in PR s pomočjo SEO. Okrepite se še danes.
- PlatoData.Network Vertical Generative Ai. Opolnomočite se. Dostopite tukaj.
- PlatoAiStream. Web3 Intelligence. Razširjeno znanje. Dostopite tukaj.
- PlatoESG. Ogljik, CleanTech, Energija, Okolje, sončna energija, Ravnanje z odpadki. Dostopite tukaj.
- PlatoHealth. Obveščanje o biotehnologiji in kliničnih preskušanjih. Dostopite tukaj.
- vir: https://www.biospace.com/article/releases/si-bone-inc-reports-record-fourth-quarter-and-full-year-2023-financial-results-and-issues-2024-guidance/?s=93
- :ima
- : je
- :ne
- ][str
- 000
- 1
- 10
- 11
- 12
- 125
- 13
- 130
- 15%
- 150
- 17
- 2%
- 2009
- 2022
- 2023
- 2024
- 26
- 27
- 30
- 31
- 32
- 33
- 4
- 400
- 46
- 5
- 6
- 7
- 8
- 9
- 90
- a
- sposobnost
- dostopna
- skladnosti
- čez
- aktivna
- dejavnosti
- dejavnost
- dejanska
- Dodatne
- Dodatne informacije
- sosednji
- Prilagojen
- Izobraževanje odraslih
- po
- vsi
- omogoča
- Prav tako
- am
- amortizacija
- zneski
- an
- analizirati
- anatomija
- in
- letno
- Predvideno
- kaj
- približno
- SE
- AS
- oceniti
- Sredstva
- povezan
- predpostavke
- At
- audio
- Na voljo
- Ravnovesje
- temeljijo
- Osnovni
- BE
- ker
- postanejo
- meni
- Prednosti
- BioSpace
- telo
- Brezpogojno
- by
- kalif
- klic
- CAN
- Kapital
- kapitalske zahteve
- kapitalizirati
- Denar
- center
- nekatere
- verige
- spremenite
- šef
- Chief Executive
- izvršni direktor
- Clara
- Potrditev
- klinični
- Zapri
- COM
- komercialna
- komercializirati
- Komisija
- Skupno
- skupna zaloga
- podjetje
- Podjetja
- v primerjavi z letom
- primerjave
- Odškodnina
- Končana
- celovito
- Izračunajte
- Konferenca
- šteje
- dosledno
- vseboval
- naprej
- nadzorom
- Core
- Ustrezno
- stroški
- bi
- CSS
- Trenutna
- Dnevi
- december
- zmanjša
- namenjen
- opredelitev
- Povpraševanje
- izkazati
- amortizacije
- opisano
- Želja
- Razvoj
- naprava
- naprave
- se razlikujejo
- razredčen
- zavrača
- razpravlja
- Motnje
- ne
- vozi
- vožnjo
- dinamika
- vsak
- Zgodnje
- vzhodni
- EBITDA
- Gospodarska
- učinek
- Učinki
- omogoča
- spodbuja
- končala
- celota
- oprema
- pravičnost
- ekvivalenti
- zlasti
- ocene
- oceniti
- Event
- dogodki
- dokazi
- presežena
- Razen
- presežek
- Izmenjava
- Komisija za izmenjavo
- zanimivo
- izvedba
- izvršni
- Izvršni direktor
- pričakovati
- pričakovanja
- pričakuje
- stroškov
- Stroški
- izrecno
- Sklad
- dejavniki
- ugodna
- izvedljivost
- februar
- vložena
- vložki
- finančna
- finančne informacije
- finančna uspešnost
- prva
- davek
- za
- obrazec
- v prihodnost
- Četrti
- Francis
- tovorni promet
- iz
- polno
- fuzija
- Prihodnost
- GAAP
- Globalno
- globus
- GLOBE NOVICE
- Cilj
- blago
- bruto
- Rast
- Navodila
- število zaposlenih
- pomoč
- tukaj
- več
- Poudarjeno
- Poudarki
- gostitelj
- HTTPS
- i
- vpliv
- prizadeti
- izboljšanje
- izboljšalo
- Izboljšanje
- in
- Inc
- vključujejo
- vključuje
- Vključno
- prihodki
- Povečajte
- povečal
- indikacije
- Podatki
- inherentno
- instrument
- obresti
- zainteresirani
- Facebook Global
- Internet
- uvesti
- invazivno
- inventar
- naložbe
- naložbe
- Investitor
- Vlagatelji
- vključujejo
- Vprašanja
- IT
- Izdelkov
- ITS
- skupno
- jpg
- kosilo
- zakon
- Vodja
- Vodstvo
- vsaj
- Led
- levo
- Vzvod
- finančni vzvod
- obveznosti
- v živo
- živi
- logo
- dolgoročna
- off
- nižje
- vzdrževati
- Znamka
- upravljanje
- upravljanje
- več
- Marža
- Tržna
- Prisotnost
- materialno
- Maj ..
- smiselna
- ukrepe
- medicinski
- medicinski pripomoček
- meritev
- milijonov
- mix
- Ponedeljek
- mesecev
- več
- Najbolj
- mišično-skeletni
- Nasdaq
- skoraj
- net
- Novo
- novi izdelki
- Newswire
- roman
- Številka
- Obveznost
- obveznice
- of
- ponujanje
- Častnik
- odmik
- on
- deluje
- poslovni odhodki
- operativno
- operacije
- or
- Ostalo
- drugi
- naši
- Outlook
- Neporavnani
- več
- bolečina
- bolniki
- peer
- za
- odstotek
- performance
- opravljeno
- izvajati
- Obdobje
- osebe
- Pionirstvo
- platon
- Platonova podatkovna inteligenca
- PlatoData
- prosim
- Točka
- pripravljeni
- predstavitev
- pritisnite
- Sporočilo za javnost
- razširjenost
- v prvi vrsti
- primarni
- Predhodna
- postopek
- Postopki
- Izdelek
- Izdelki
- Napredek
- Ponosni
- zagotavlja
- publikacije
- javno
- četrtletje
- Naključno
- terjatev
- nedavno
- zapis
- evidence
- Zmanjšanje
- razmišljanje
- odseva
- o
- registriranih
- povračilo
- povezane
- sprostitev
- Replay
- Prijavljeno
- Poročila
- predstavlja
- obvezna
- Zahteve
- Raziskave
- raziskave in razvoj
- Reserve
- pridržane
- spoštovanje
- povzroči
- Rezultati
- prihodki
- rast prihodkov
- pregleda
- Pregledal
- popravki
- pravice
- Tveganje
- dejavniki tveganja
- tveganja
- s
- Varnost
- Je dejal
- Božiček
- SEC
- drugi
- Oddelek
- Vrednostni papirji
- Securities and Exchange Commission
- Delite s prijatelji, znanci, družino in partnerji :-)
- Delnice
- shouldnt
- pomemben
- silvia
- podobno
- saj
- spletna stran
- manj
- rešitve
- Reševanje
- Izjave
- Stellar
- zaloge
- Močno
- precejšen
- uspeh
- taka
- dobavi
- dobavne verige
- Podprti
- Podpira
- Surgery
- kirurški
- sistemi
- ciljna
- Tehnologije
- Tehnologija
- kot
- da
- O
- njihove
- te
- jih
- ta
- tisti,
- tisoče
- čas
- čas
- z naslovom
- do
- danes
- Skupaj za plačilo
- proti
- blagovne znamke
- potovanja
- Zdravljenje
- poskusi
- dva
- nas
- nerevidirano
- negotovosti
- pod
- opravi
- v postopku
- zavezujeta
- edinstven
- Nadgradnja
- posodobitve
- us
- Uporaba
- uporaba
- Rabljeni
- koristno
- uporablja
- uporabo
- obisk
- Obseg
- je
- we
- šibkost
- Spletna stran
- Dobro
- so bili
- kdaj
- ki
- medtem
- bo
- z
- po vsem svetu
- leto
- zefirnet